AcelRx Pharmaceuticals

AcelRx Pharmaceuticals EBITDA per Employee

Delisted

The EBITDA per Employee of AcelRx Pharmaceuticals (ACRX) as of Nov 2, 2026 is -1.41 M USD. In the previous year, EBITDA per Employee was -3.05 M USD — a change of -53.90% (higher).

EBITDA per Employee

-1.41 MUSD

YoY

-53.90%

Last updated:

EBITDA per Employee of AcelRx Pharmaceuticals is 2023 -1.41 M USD. EBITDA per Employee of AcelRx Pharmaceuticals was 2022 -3.05 M USD. It decreases by -53.90% higher compared to the previous year.

The AcelRx Pharmaceuticals EBITDA per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA per Employee
Date
EBITDA per Employee
Jan 1, 2016
-2.66 M USD
Jan 1, 2017
-3.22 M USD
Jan 1, 2018
-2.98 M USD
Jan 1, 2019
-4.52 M USD
Jan 1, 2020
-3.41 M USD
Jan 1, 2021
-3.00 M USD
Jan 1, 2022
-3.05 M USD
Jan 1, 2023
-1.41 M USD
The AcelRx Pharmaceuticals EBITDA per Employee history
YEAREBITDA per EmployeeYoY
-1.41 MUSD-53.90%
-3.05 MUSD+1.86%
-3.00 MUSD-12.20%
-3.41 MUSD-24.43%
-4.52 MUSD+51.72%
-2.98 MUSD-7.64%
-3.22 MUSD+21.04%
-2.66 MUSD+60.15%
-1.66 MUSD-47.00%
-3.14 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

AcelRx Pharmaceuticals Stock analysis

What does AcelRx Pharmaceuticals do? AcelRx Pharmaceuticals Inc. is a California-based company specializing in the manufacturing of pain relief medications. The company was founded in 2005 and has since become an innovator in the development of pain medications. AcelRx's business model involves selling its patented products to hospitals and other healthcare facilities, and it is currently expanding into the global market. The company focuses on developing pain medications for emergency medicine and palliative care, with a particular emphasis on delivering medications through sprays or injections for fast-acting relief. AcelRx offers products such as Zalviso, a pain reliever based on Fentanyl nasal sprays used for post-operative pain, and Dsuvia, a sublingual tablet containing the active ingredient Sufentanil for severe pain. The FDA has approved Dsuvia as safe and effective. AcelRx has also entered partnerships with other pharmaceutical companies, such as Grünenthal and Chinese company R-Pharm, to bring its products to the international market. The company is committed to investing in research and development for innovative pain relief solutions, including a new research program targeting the development of medications for neuropathic pain. AcelRx Pharmaceuticals is a positive example of how modern pharmaceuticals can improve healthcare and quality of life. The company has demonstrated its potential through dedication and continuous research and development, and it is likely to make even greater contributions in the future. AcelRx Pharmaceuticals is one of the most popular companies on Eulerpool.

Frequently Asked Questions about AcelRx Pharmaceuticals stock

EBITDA per Employee of AcelRx Pharmaceuticals is -1.41 M USD in 2023.

EBITDA per Employee of AcelRx Pharmaceuticals changed from -3.05 M USD to -1.41 M USD, representing a -53.90% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBITDA per Employee AcelRx Pharmaceuticals since 2006 – with annual values, charts, and detailed analysis.

EBITDA per employee measures operating cash earnings generated per employee, showing workforce productivity before depreciation and financing effects.

EBITDA per Employee's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA per Employee's AcelRx Pharmaceuticals historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Workforce — AcelRx Pharmaceuticals

All Key Metrics — AcelRx Pharmaceuticals